Study Favors As-Needed Treatment Over Maintenance Therapy for Patients with …NEWS.GNOM.ES (press release)ES/ – Asymptomatic patients diagnosed with nonbulky follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma, have traditionally been w…
Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient …PR Newswire (press release)The first clinical trial to directly compare rituximab with the new anti-CD20 monoclonal antibody obinutuzumab for the treatment of relapsed no…
Patients with Relapsed/Refractory Hodgkin's Lymphoma Benefit from VTEPA …Monthly Prescribing ReferenceOf patients with DLBCL, 70% had received prior salvage therapy with rituximab + ifosfamide, carboplatin, and etoposide (ICE) and 16% received ot…
Pixantrone Instead of Doxorubicin in CHOP-R Regimen Has Comparable Efficacy …Monthly Prescribing ReferenceSAN DIEGO, CA—For patients with untreated diffuse large B-cell lymphoma (DLBCL), CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisol…
Sarah Cannon Research Institute Presents Findings of Blood Cancer Clinical …MarketWatch (press release)… excluding Transplantation: (PI3K) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab Poster I and/or Bendamustine in Patients with Rel…
Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic …MarketWatch (press release)An oral presentation (Abstract 168), entitled Ad-ISF35-Transduced Autologous Cells In Combination with Fludarabine, Cyclophosphamide, Rituximab (FCR) …
Evidence Base for VELCADE Builds as new Data is Presented at 53rd American …PR Newswire UK (press release)Analyses of the phase 3 LYM3001 trial identified biomarker combinations present in a third of patients offering a significant progression free s…
Elevated doses of chemotherapy may benefit younger lymphoma patientsHemOncTodayResearchers found that an intensive form of chemotherapy — when combined with the monoclonal antibody drug rituximab (Rituxan; Genentech/Idec Pharmaceuticals) — could re…
TVs to Biologics: Samsung Dives into Biosimilars with $300M Biogen Idec JVBioWorld OnlineIt markets Tysabri (natalizumab) and Avonex (Interferon beta-1a) for multiple sclerosis, and Rituxan (rituximab) for non-Hodgkin lymphoma. Its development pipeline…
Ricerca per Alzheimer, schizofrenia e sclerosi multiplaANSA.itNel dettaglio, si tratta di "Daclizumab", molecola sviluppata in partnership con Biogen, in fase tre di sviluppo per il trattamento della sclerosi multipla recidivante-remittente, …